Ovarian Cancer Stem Cells and Tumor Microenvironment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 4039

Special Issue Editor


E-Mail Website
Guest Editor
College of Sciences Biology, San Diego State University, San Diego, CA, USA
Interests: Ovarian cancer biology; cancer stem-like cells; NF-kB signaling; tumor microenvironment

Special Issue Information

Dear Colleagues,

The ovarian tumor microenvironment is a dynamic ecosystem composed of a heterogenous collection of tumor cells, immune cells, stromal cells, extracellular matrix proteins, and vasculature. A variety of soluble factors including cytokines, chemokines, growth factors and exosomes are critical for shaping the tumor microenvironment and influencing tumor cell phenotypes and responses to therapy. While bulk tumor cells have a more differentiated phenotype and are sensitive to chemotherapy; a minority of relatively undifferentiated tumor cells exhibit features of normal stem cells that allow them to evade chemotherapy and generate heterogeneous tumors. These cells are commonly referred to as cancer stem/stem-like cells (CSCs) or tumor-initiating cells (TICs). It is thought that CSCs are responsible for the high rate of relapse experienced by high-grade serous ovarian cancer patients and efforts to target these cells are of great clinical interest.

Research over the last decade has focused on identifying and characterizing ovarian CSCs to delineate reliable markers such as surface expression of LGR5, CD117, or CD133 in combination with aldehyde dehydrogenase (ALDH) activity and reproducible phenotypes such as tumor-initiation capacity, drug resistance, and the ability to undergo asymmetric division. Although CSCs may be preexisting and their deregulation responsible for initial tumor formation, recent findings indicate that CSCs can be induced in bulk tumor cells through paracrine activation of signaling pathways that sustain stem-like features. Dynamic communication between tumor cells, macrophages, fibroblasts, and adipocytes is implicated in supporting CSCs and creating a pro-tumorigenic niche that facilitates chemotherapy resistance and immune evasion. A better understanding of the biological mechanisms that sustain ovarian CSCs and the role of the tumor microenvironment in this process will lead to new therapeutic targets to overcome chemotherapy resistance, prevent relapse, and improve survival of ovarian cancer patients. This Special Issue will highlight the role of the ovarian tumor microenvironment in CSC maintenance, immune evasion, and response to therapeutics, covering basic and translational studies that advance our understanding of this dynamic biological system.

Dr. Carrie House
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer stem cells
  • stem-like cells
  • tumor initiation
  • chemotherapy resistance
  • tumor relapse
  • tumor microenvironment
  • tumor immunology
  • stromal cells
  • cancer-associated fibroblasts

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 3148 KiB  
Article
Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour
by Valéria Tavares, Joana Savva-Bordalo, Mariana Rei, Joana Liz-Pimenta, Joana Assis, Deolinda Pereira and Rui Medeiros
Cancers 2024, 16(13), 2356; https://doi.org/10.3390/cancers16132356 - 27 Jun 2024
Cited by 1 | Viewed by 1131
Abstract
Ovarian cancer (OC) is the deadliest gynaecological malignancy. Identifying new prognostic biomarkers is an important research field. Haemostatic components together with leukocytes can drive cancer progression while increasing the susceptibility to venous thromboembolism (VTE) through immunothrombosis. Unravelling the underlying complex interactions offers the [...] Read more.
Ovarian cancer (OC) is the deadliest gynaecological malignancy. Identifying new prognostic biomarkers is an important research field. Haemostatic components together with leukocytes can drive cancer progression while increasing the susceptibility to venous thromboembolism (VTE) through immunothrombosis. Unravelling the underlying complex interactions offers the prospect of uncovering relevant OC prognostic biomarkers, predictors of cancer-associated thrombosis (CAT), and even potential targets for cancer therapy. Thus, this study evaluated the expression of F3, F5, F8, F13A1, TFPI1, and THBD in peripheral blood cells (PBCs) of 52 OC patients. Those with VTE after tumour diagnosis had a worse overall survival (OS) compared to their counterparts (mean OS of 13.8 ± 4.1 months and 47.9 ± 5.7 months, respectively; log-rank test, p = 0.001). Low pre-chemotherapy F3 and F8 expression levels were associated with a higher susceptibility for OC-related VTE after tumour diagnosis (χ2, p < 0.05). Regardless of thrombogenesis, patients with low baseline F8 expression had a shorter progression-free survival (PFS) than their counterparts (adjusted hazard ratio (aHR) = 2.54; p = 0.021). Among those who were not under platelet anti-aggregation therapy, low F8 levels were also associated with a shorter OS (aHR = 6.16; p = 0.006). Moving forward, efforts should focus on external validation in larger cohorts. Full article
(This article belongs to the Special Issue Ovarian Cancer Stem Cells and Tumor Microenvironment)
Show Figures

Graphical abstract

Review

Jump to: Research

28 pages, 840 KiB  
Review
The Role of Cancer Stem Cell Markers in Ovarian Cancer
by Karolina Frąszczak and Bartłomiej Barczyński
Cancers 2024, 16(1), 40; https://doi.org/10.3390/cancers16010040 - 20 Dec 2023
Cited by 3 | Viewed by 2506
Abstract
Ovarian cancer is the most lethal gynaecological cancer and the eighth most common female cancer. The early diagnosis of ovarian cancer remains a clinical problem despite the significant development of technology. Nearly 70% of patients with ovarian cancer are diagnosed with stages III–IV [...] Read more.
Ovarian cancer is the most lethal gynaecological cancer and the eighth most common female cancer. The early diagnosis of ovarian cancer remains a clinical problem despite the significant development of technology. Nearly 70% of patients with ovarian cancer are diagnosed with stages III–IV metastatic disease. Reliable diagnostic and prognostic biomarkers are currently lacking. Ovarian cancer recurrence and resistance to chemotherapy pose vital problems and translate into poor outcomes. Cancer stem cells appear to be responsible for tumour recurrence resulting from chemotherapeutic resistance. These cells are also crucial for tumour initiation due to the ability to self-renew, differentiate, avoid immune destruction, and promote inflammation and angiogenesis. Studies have confirmed an association between CSC occurrence and resistance to chemotherapy, subsequent metastases, and cancer relapses. Therefore, the elimination of CSCs appears important for overcoming drug resistance and improving prognoses. This review focuses on the expression of selected ovarian CSC markers, including CD133, CD44, CD24, CD117, and aldehyde dehydrogenase 1, which show potential prognostic significance. Some markers expressed on the surface of CSCs correlate with clinical features and can be used for the diagnosis and prognosis of ovarian cancer. However, due to the heterogeneity and plasticity of CSCs, the determination of specific CSC phenotypes is difficult. Full article
(This article belongs to the Special Issue Ovarian Cancer Stem Cells and Tumor Microenvironment)
Show Figures

Figure 1

Back to TopTop